Ferrer 扩大了与 United Therapeutics Corp 的 Tyvaso® 分销协议，以用于治疗肺部疾病的新适应症。 Ferrer expands Tyvaso® distribution agreement with United Therapeutics Corp for new indications in pulmonary diseases.

Ferrer 扩大了与 United Therapeutics Corp 的 Tyvaso®（曲前列尼尔吸入溶液）分销协议，用于治疗肺动脉高压 (ILD) 和 PAH。 Ferrer expands distribution agreement with United Therapeutics Corp for Tyvaso® (treprostinil inhalation solution) to treat Pulmonary Hypertension-ILD & PAH. 扩大后的交易包括特发性肺纤维化和进行性肺纤维化的新潜在适应症。 The expanded deal includes new potential indications for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis. Ferrer 被任命为除美国、加拿大、日本、中国和以色列以外的全球独家经销商，该药物目前处于第 3 阶段试验阶段。 Ferrer is appointed as the exclusive worldwide distributor, except in US, Canada, Japan, China, and Israel, with the drug currently in Phase 3 trials.